Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.

Saved in:
Bibliographic Details
Title: Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.
Authors: Li Z; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China., Tang Y; State Key Laboratory of Multimodal Artificial Intelligence Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China., Chen Z; Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing, China., Liu G; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China., Yao W; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China., Li G; Hematologic Disease Laboratory, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing, China., Cheng X; Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China., Peng Y; Center for Clinical Epidemiology and Evidence-based Medicine, Capital Medical University, Beijing, China., Cai S; Center for Clinical Epidemiology and Evidence-based Medicine, Capital Medical University, Beijing, China., Cui C; State Key Laboratory of Multimodal Artificial Intelligence Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China., Ai D; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Pediatrics Departments, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China., Zhang J; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China; Pediatrics Departments, National Key Discipline of Pediatrics, Capital Medical University, Beijing, China., Poon MC; Departments of Medicine, Pediatrics and Oncology, University of Calgary Cumming School of Medicine, Calgary, Canada., Zhang W; State Key Laboratory of Multimodal Artificial Intelligence Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China. Electronic address: zhangwenshengia@hotmail.com., Wu R; Hemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Electronic address: runhuiwu@hotmail.com.
Source: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2025 Aug; Vol. 23 (8), pp. 2436-2448. Date of Electronic Publication: 2025 Apr 24.
Publication Type: Clinical Trial, Phase IV; Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101170508 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7836 (Electronic) Linking ISSN: 15387836 NLM ISO Abbreviation: J Thromb Haemost Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-7836
DOI:10.1016/j.jtha.2025.04.015